PAK1 and posterior cortical atrophy: By targeting a protein whose expression is increased in PCa cells (PAK1), IPA-3 is expected to have greater specificity and selectivity compared to chemotherapy agents that target microtubules or DNA, since it targets the protein that is not detected in non-cancerous prostate tissue.